Structure (Image 1)
Doxazosin Tablet
Product Images NDC 50090-6401
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 50090-6401). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (Image 2)
The text describes the results of three studies evaluating the efficacy of doxazosin mesylate in treating benign prostatic hyperplasia (BPH). The studies measured changes in maximum flow rate and symptom score (measured using the AUA questionnaire or Modified Boyarsky Questionnaire) after titration to a fixed or maximum dose of doxazosin mesylate or placebo over a period of 12-14 weeks. The results show that doxazosin mesylate leads to improvements in maximum flow rate and symptom score compared to placebo, with statistically significant differences (p < 0.05) observed for some doses in some studies.*
1 (Image 3)
This text provides information about a clinical study that measured the mean change in total symptom scores and maximum urinary flow rate in patients receiving doxazosin titration or placebo treatment over a duration of several weeks. The graph shows a significant improvement in symptom scores in patients receiving doxazosin compared to placebo, and a significant increase in maximum urinary flow rate from baseline in patients receiving doxazosin. The study used a p-value of 0.05 to determine statistical significance.*
Label Image (Lbl500906401)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
